Expert Consensus on Clinical Application of Yifei Zhike Capsules
10.13422/j.cnki.syfjx.20251391
- VernacularTitle:益肺止咳胶囊临床应用专家共识
- Author:
Xin CUI
1
;
Hongchun ZHANG
2
;
Weiwei GUO
3
;
Chengjun BAN
4
;
Zhifei WANG
1
;
Yuanyuan LI
1
;
Yingjie ZHI
1
;
Xuefeng YU
5
;
Yanming XIE
1
Author Information
1. Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences， Beijing 100700，China
2. China-Japan Friendship Hospital，Beijing 100029，China
3. Qiandongnan Institute of Ethnic Medicine and Affiliated Miao Hospital，Guiyang 556099，China
4. Dongzhimen Hospital，Beijing University of Chinese Medicine，Beijing 101121，China
5. The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine，Shenyang 110034，China
- Publication Type:Journal Article
- Keywords:
expert consensus;
Yifei Zhike capsules;
respiration;
clinical application;
Miao medicine
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(11):218-224
- CountryChina
- Language:Chinese
-
Abstract:
As an exclusive Miao medicine of Honwing Pharma （Guizhou） Co. Ltd.， Yifei Zhike capsules are both a prescription drug and an over-the-counter （OTC） drug. Its main ingredients include Ranunculus ternatus and Panax notoginseng. With the effects of nourishing Yin and moistening the lungs， as well as relieving cough and reducing phlegm， Yifei Zhike capsules are often used in the treatment of acute and chronic bronchitis， pulmonary tuberculosis， and other diseases. However， there is insufficient understanding of their efficacy， suitable syndromes， and safety in clinical practice， with a lack of relevant expert consensus on clinical application. To standardize their clinical application， 30 experts from the fields of respiratory medicine， pharmacy， and evidence-based medicine were invited to develop an Expert Consensus on the Clinical Application of Yifei Zhike Capsules （Consensus for short） through evidence-based medicine methods. The Consensus clarified the syndrome characteristics， disease stages， dosages， treatment courses， combined medication， and other norms in the treatment of acute/chronic bronchitis and pulmonary tuberculosis and could be applicable to clinical physicians and pharmacists in medical and health institutions at all levels. In disease diagnosis， it provided diagnostic criteria for traditional Chinese medicine and Western medicine and clarified that the suitable traditional Chinese medicine syndrome was the syndrome of Qi-Yin deficiency with intermingled phlegm-blood stasis. Clinical studies have confirmed that Yifei Zhike capsules combined with standard anti-tuberculosis therapy can effectively improve the symptoms of pulmonary tuberculosis patients， increase the sputum smear conversion rate， and promote the absorption of lesions. When treating acute cough caused by respiratory tract infections， Yifei Zhike capsules can increase the markedly effective rate and the seven-day disappearance rate of cough symptoms. Meanwhile， recommendations for specific usage， dosages， and treatment courses were given for different diseases， and it was pointed out that long-term medication required key monitoring of adverse reactions. In safety， the adverse reactions of Yifei Zhike capsules involved multiple aspects such as the digestive system and allergic reactions， and pregnant women and women during menstruation were prohibited from using it. In addition， modern research has shown that Yifei Zhike capsules have an adjuvant therapeutic effect on tuberculous pleurisy and may be effective for inflammatory and benign pulmonary nodules. However， further research should be conducted on the toxicological safety of long-term medication. The formulation of the Consensus provides a scientific basis for the rational clinical application of Yifei Zhike capsules， which helps to improve clinical efficacy and reduce medication risks.
